Ignite Creation Date:
2024-05-05 @ 10:23 PM
Last Modification Date:
2024-10-26 @ 10:17 AM
Study NCT ID:
NCT01092104
Status:
COMPLETED
Last Update Posted:
2013-07-10
First Post:
2010-03-22
Brief Title:
A Proof of Concept Study to Evaluate the Antiviral Activity Safety and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected Antiretroviral Treatment-Experienced CCR5 Antagonist-Naïve Patients
Sponsor:
Tobira Therapeutics Inc
Organization:
Tobira Therapeutics Inc
Study Overview
Official Title:
A Proof of Concept Multiple Dose-Escalating Study to Evaluate the Antiviral Activity Safety and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected Antiretroviral Treatment-Experienced CCR5 Antagonist-Naïve Patients
Status:
COMPLETED
Status Verified Date:
2013-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A double-blind randomized placebo-controlled dose-escalating study to assess the antiviral activity safety tolerability and pharmacokinetics PK of the CCR5 antagonist TBR 652 monotherapy dosed orally once daily QD for 10 days in HIV 1-infected antiretroviral treatment-experienced CCR5 antagonist-naïve patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None